Balancing the Risk-Benefit Ratio of Immune Checkpoint Inhibitor and Anti-VEGF Combination Therapy in Renal Cell Carcinoma: A Systematic Review and Meta-Analysis.

Front Oncol · 2021 · PMC8552014 · PMID 34722290

Europe PMC DOI

hedged sentences

—

closest p

—

boldest claim

The sentences

failed to reach statistical significanceno p-value reported

In the current study, the assumption that patients with PD-L1 expression could receive more benefits from ICI and anti-VEGF combination therapy was born out by the analysis of PFS and OS in the PD-L1-positive subgroup, while the HR of PFS in PD-L1-negative subgroup failed to reach statistical significance.

also in 6,035 other papers

did not reach statistical significanceno p-value reported

Since the RR of any- and high-grade diarrhea did not reach statistical significance, it seems that the combination therapy did not increase the risk of developing diarrhea.

also in 111,027 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.